04.02.2014 • NewsDede WillamsCMIDaiichi Sankyo

Daiichi Sankyo Pledges “Bold Action” on Ranbaxy Ban

Japan's Daiichi Sankyo said it would send personnel to help resolve problems at a production facility of its drugmaking subsidiary Ranbaxy at Toansa in India's northern state of Punjab. The U.S. Food and Drug Administration has banned exports from the plants due to manufacturing violations. It is the fourth Ranbaxy plant to be shut out of the U.S. market.
Manabu Sakai, senior executive officer at Daiichi Sankyo, told an earnings briefing that the company wants to prepare "a more aggressive, more drastic response" to the ban.

Following an inspection completed on Jan. 11, the FDA said in late January that Ranbaxy is prohibited from making and selling pharmaceutical ingredients from Toansa "to prevent substandard quality products from reaching U.S. consumers."

The U.S. regulator had previously barred products from the company's facilities in Paonta Sahib, Dewas and Mohali in India as part of a 2012 consent decree designed to ensure compliance with good manufacturing practices.

At the Toansa facility the FDA said it found that Ranbaxy had re-tested raw materials and other ingredients after the items failed analytical testing in order to produce acceptable findings, but the company did not report or investigate the failures.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

most read

Photo
21.03.2025 • News

What’s Next for Pharma Supply Chains?

Sudden shifts in demand, supply shortages and global collapse have put immense pressure on pharmaceutical logistics. To address these challenges, PHARMAP 2025 brings together industry experts to discover AI-driven supply chain optimisation, strategic logistics partnerships and digital solutions that enhance efficiency and resilience in the pharmaceutical supply chain.